KR920700221A - Novel Linin Inhibitor Peptides with Polar N-Terminal Groups - Google Patents

Novel Linin Inhibitor Peptides with Polar N-Terminal Groups

Info

Publication number
KR920700221A
KR920700221A KR1019900702636A KR900702636A KR920700221A KR 920700221 A KR920700221 A KR 920700221A KR 1019900702636 A KR1019900702636 A KR 1019900702636A KR 900702636 A KR900702636 A KR 900702636A KR 920700221 A KR920700221 A KR 920700221A
Authority
KR
South Korea
Prior art keywords
methyl
amino
carbonyl
phe
hydroxy
Prior art date
Application number
KR1019900702636A
Other languages
Korean (ko)
Inventor
타이스리봉스 수비트
Original Assignee
원본미기재
디 엎죤 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 디 엎죤 캄파니 filed Critical 원본미기재
Publication of KR920700221A publication Critical patent/KR920700221A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0227—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the (partial) peptide sequence -Phe-His-NH-(X)2-C(=0)-, e.g. Renin-inhibitors with n = 2 - 6; for n > 6 see C07K5/06 - C07K5/10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

내용 없음No content

Description

극성 N－말단기들을 갖는 신규 리닌 억제인자 펩티드Novel Linin Inhibitor Peptides with Polar N-Terminal Groups

내용없음No content

Claims (9)

리닌 기질(안지오텐시노겐(angiotensinogen))의 10,11위치에 상응하는 비－쪼개짐성 전이 상태 삽입물을 갖고 N－말단에 하기 일반식 L1부분을 갖는 펩티드:A peptide having a non-cleavable transition state insert corresponding to positions 10,11 of a linin substrate (angiotensinogen) and having the following general formula L 1 moiety at the N-terminus: (상기식에서, X1은 a) H2N－, b) H2NC(CH3)2－, c) HO2C－, d) (H2N)(HO2C)CH－, 또는 e) (HO)2P(O)O－이고, n은 1－5이다.)Wherein X 1 is a) H 2 N-, b) H 2 NC (CH 3 ) 2- , c) HO 2 C-, d) (H 2 N) (HO 2 C) CH-, or e (HO) 2 P (O) O-, n is 1-5.) 리닌 기질(안지오텐시노겐)의 10,11위치에 상응하는 비－쪼개짐성 전이 상태 삽입물을 갖는 펩티드에 있어서, N－말단에 하기 일반식 L1부분을 펩티드내 포함함을 개선점으로 하는 펩티드:Peptides having a non-cleavable transition state insert corresponding to positions 10 and 11 of the linin substrate (angiotensinogen), wherein the peptide includes the following general formula L 1 moiety at the N-terminus as an improvement: (상기식에서, X1은 a) H2N－, b) H2NC(CH3)2－, c) HO2C－, d) (H2N)(HO2C)CH－, 또는 e) (HO)2P(O)O－이고, n은 1－5이다.)Wherein X 1 is a) H 2 N-, b) H 2 NC (CH 3 ) 2- , c) HO 2 C-, d) (H 2 N) (HO 2 C) CH-, or e (HO) 2 P (O) O-, n is 1-5.) 제1항에 있어서, 하기 일반식(Ⅰ)의 펩티드 또는 그의 카르복시－, 아미노－, 또는 다른 반응성기 보호된 형태 또는 그의 제약학적으로 허용가능한 산 또는 염기 부가염:The peptide or a carboxy-, amino-, or other reactive group protected form thereof of the formula (I) or a pharmaceutically acceptable acid or base addition salt thereof: A6－B7－C8－D9－E10－F11－G12－H13(Ⅰ)A 6 -B 7 -C 8 -D 9 -E 10 -F 11 -G 12 -H 13 (I) 상기식에서, A6은 하기 일반식 L1이 일가부분이고:Wherein A 6 is a monovalent moiety wherein the general formula L 1 is: B7은 부재하거나 하기 일반식 L2의 이가부분이고;B 7 is absent or a divalent moiety of the general formula L 2 ; C8은 하기 일반식 L3또는 L4의 이가 부분이고;C 8 is a divalent moiety of the general formula L 3 or L 4 ; D9은 하기 일반식 L4또는 L5의 이가 부분이고;D 9 is a divalent moiety of the general formula L 4 or L 5 ; E10－F11은 하기일반식 L6－L10중 임의의 것이 이가부분이거나 일반식 L11의 일가부분이고;E 10 -F 11 is any of the following general formula L 6 -L 10 is a divalent moiety or a monovalent moiety of general formula L 11 ; H13은 a)－O－R5또는 b)－N(R1)(R5)이고; 식들에서 X1은 a) H2N－, b) H2NC(yCH3)2－, c) HO2C－, d) (H2N)(HO2C)CH－, 또는 e)이고, Q1은 a)－CH2－, －CH(OH)－, c)－O－, 또는 d)－S－이고 M1은 a)－C(O)－ 또는 b)－CH2이고; V1은 a)－O－또는 b)－N(R1)－이고; Y1은 a)－OH 또는 b)－NH2이고; P1은 a)－N3, b)－CN, C1－C6알킬, d)C1－C6시클로알킬, e)아릴, 또는 f)Het 이고 m은 1또는 2이고, n은 1－5이고, p는 0－5이고, 아릴은 하기중 0－3개로 치환된, 페닐 또는 나프틸이고; a)C1－C5알킬, b)히드록시, c)히드록시(C1－C5알킬), d)C1－C5알콕시, e) 아미노 f)아미노(C1－C5알킬), g)할로겐, h)－CHO, i)－CO2H, j)－CO2(C1－C5알킬), k)－CONH2, l)－CONH(C1－C5 알킬), m)니트로, n)머캅토, o)머캅토(C1－C5알킬), p)－SO3H, q)－SO2NH2, r)－CN;H 13 is a) -O-R 5 or b) -N (R 1 ) (R 5 ); Where X 1 is a) H 2 N-, b) H 2 NC (yCH 3 ) 2- , c) HO 2 C-, d) (H 2 N) (HO 2 C) CH-, or e) Q 1 is a) -CH 2- , -CH (OH)-, c) -O-, or d) -S-, and M 1 is a) -C (O)-or b) -CH 2 ; V 1 is a) -O- or b) -N (R 1 )-; Y 1 is a) -OH or b) -NH 2 ; P 1 is a) -N 3 , b) -CN, C 1 -C 6 alkyl, d) C 1 -C 6 cycloalkyl, e) aryl, or f) Het and m is 1 or 2, n is 1 -5, p is 0-5, and aryl is phenyl or naphthyl, substituted by 0-3 below; a) C 1 -C 5 alkyl, b) hydroxy, c) hydroxy (C 1 -C 5 alkyl), d) C 1 -C 5 alkoxy, e) amino f) amino (C 1 -C 5 alkyl) , g) halogen, h) -CHO, i) -CO 2 H, j) -CO 2 (C 1 -C 5 alkyl), k) -CONH 2 , l) -CONH (C 1 -C5 alkyl), m ) Nitro, n) mercapto, o) mercapto (C 1 -C 5 alkyl), p) -SO 3 H, q) -SO 2 NH 2 , r) -CN; Het는 1－3개 이종원자(질소, 산, 황)를 함유하고, 임의의 비시클릭기를 포함하는 5－또는 6－원포화 또는 불포화고리이고, (이때, 상기 헤테로시클릭 고리중 임의의 것은 벤젠 고리 또는 다른 헤테로사이클로 융합되고, 화학적으로 가능하다면, 상기 질소 및 황 원자는 산화 형태일수 있다); 이는 하기중 0－3개로 치환되고 : a)C1－C5알킬, b)히드록시, c)히드록시(C1－C5알킬), d)C1－C5알콕시, e)아미노, f)아미노(C1－C5알킬), g)할로겐, h)－CHO, i)－CO2H, j)－CO2(C1－C5알킬), k)－CONH2, l)－CONH(C1－C5알킬), m)니트로, n)머캅토, o)머캅토(C1－C5알킬), p)－SO3H, q)－SO2NH2, r)－CN;Het is a 5- or 6-membered or unsaturated ring containing 1-3 heteroatoms (nitrogen, acid, sulfur) and containing any bicyclic group, wherein any of said heterocyclic rings Fused to a benzene ring or other heterocycle and, where chemically possible, the nitrogen and sulfur atoms may be in oxidized form); Which is substituted with 0-3 of the following: a) C 1 -C 5 alkyl, b) hydroxy, c) hydroxy (C 1 -C 5 alkyl), d) C 1 -C 5 alkoxy, e) amino, f) amino (C 1 -C 5 alkyl), g) halogen, h) -CHO, i) -CO 2 H, j) -CO 2 (C 1 -C 5 alkyl), k) -CONH 2 , l) -CONH (C 1 -C 5 alkyl), m) nitro, n) mercapto, o) mercapto (C 1 -C 5 alkyl), p) -SO 3 H, q) -SO 2 NH 2 , r) -CN; R1은 a)수소 또는 b)C1－C5알킬이고; R2는 a)수소 b)C1－C5알킬, c)－(CH2)p－ 아릴, d)－(CH2)p－Het, e)－(CH2)p－CO2H, f)－(CH2)p－NH2, g)－(CH2)p－CH(NH2) (CO2H), h)C3－C7시클로알킬, 또는 i)1－또는 2－아다민틸이고;R 1 is a) hydrogen or b) C 1 -C 5 alkyl; R 2 is a) hydrogen b) C 1 -C 5 alkyl, c)-(CH 2 ) p-aryl, d)-(CH 2 ) p-Het, e)-(CH 2 ) p-CO 2 H, f)-(CH 2 ) p-NH 2 , g)-(CH 2 ) p-CH (NH 2 ) (CO 2 H), h) C 3 -C 7 cycloalkyl, or i) 1- or 2- Adamantyl; R3는 a)수소, b)C1－C5알킬, c)아릴, d)C3－C7시클로알킬, e)Het, f)C1－C3알콕시, 또는 g)C1－C3알킬티오이고;R 3 is a) hydrogen, b) C 1 -C 5 alkyl, c) aryl, d) C 3 -C 7 cycloalkyl, e) Het, f) C 1 -C 3 alkoxy, or g) C 1 -C 3 alkylthio; R4는 a)수소, b)C1－C8알킬, c)C3－C7시클로알킬, 또는 d)－CH(Ra)(R6)이고;R 4 is a) hydrogen, b) C 1 -C 8 alkyl, c) C 3 -C 7 cycloalkyl, or d) -CH (R a ) (R 6 ); R5는 R2는 a)수소 b)C1－C10알킬, c)－(CH2)p－ 알킬, d)－(CH2)p－Het, e)－(CH2)p－ 시클로알킬, f)－(CH2)p－CH(NH2)(CO2)H, g)－CR1((CH2)p NH2)C(O)－Het, 또는 h)－(CH2)n－R7이고;R 5 is R 2 is a) hydrogen b) C 1 -C 10 alkyl, c)-(CH 2 ) p-alkyl, d)-(CH 2 ) p-Het, e)-(CH 2 ) p-cyclo Alkyl, f)-(CH 2 ) p-CH (NH 2 ) (CO 2 ) H, g) -CR 1 ((CH 2 ) p NH 2 ) C (O) -Het, or h)-(CH 2 ) n-R 7 ; R6은 a)수소, b)히드록시, c)C1－C5알킬, d)C3－C7시클로알킬, e)아릴, f)Het, g)C1－C3알콕시, 또는 h)C1－C3알킬티오이고;R 6 is a) hydrogen, b) hydroxy, c) C 1 -C 5 alkyl, d) C 3 -C 7 cycloalkyl, e) aryl, f) Het, g) C 1 -C 3 alkoxy, or h ) C 1 -C 3 alkylthio; R7은 a)히드록시, b)아미노, c)－CO2H, d)－SO3H, e)－SO2NH2, f)구아디닐, 또는 g)플리히드록시－치환－알킬 부분이며, 각각의 발생의 경우 정의된 변수 모두가 독립적으로 가변하고, 단, l)E10－F11이 L11일때, G12및 H13모두는 부재하고, 2)X1이 H2N－, H2NC(CH3)2－ 또는 HO2C－ 일때 E10－F11은 L11이 아니다.R 7 is a) hydroxy, b) amino, c) -CO 2 H, d) -SO 3 H, e) -SO 2 NH 2 , f) guadidinyl, or g) polyhydroxy-substituted-alkyl Part, and for each occurrence all of the defined variables are independently variable, provided that when l) E 10 -F 11 is L 11 , both G 12 and H 13 are absent and 2) X 1 is H 2 N E 10 -F 11 is not L 11 when-, H 2 NC (CH 3 ) 2 -or HO 2 C- 제3항에 있어서, A6은 일반식 L1(이때, X1은 (H2N) (HO2C)CH－이고, n은 2이다)의 일가 부분이고; B7은 부재하거나, Pro 또는 그의 유도체이고; C8은 Phe, (OCH3)Tyr 또는 그의 유도체이고; D9는 N－MeHis, His β－Asp 또는 그의 유도체이고; E10－F11은 LVA, CVA, CVG 또는 그의 유도체이고; G12는 부재하거나, Ile 또는 그의 유도체이고; H13은 AMP, AMP－NO, MBA 또는 NH(CH2)4CH(NH2)(COOH)인 펩티드.The compound of claim 3, wherein A 6 is a monovalent moiety of the general formula L 1 , wherein X 1 is (H 2 N) (HO 2 C) CH—, n is 2; B 7 is absent or Pro or a derivative thereof; C 8 is Phe, (OCH 3 ) Tyr or a derivative thereof; D 9 is N-MeHis, His β-Asp or a derivative thereof; E 10 -F 11 is LVA, CVA, CVG or a derivative thereof; G 12 is absent or Ile or a derivative thereof; H 13 is a peptide which is AMP, AMP-NO, MBA or NH (CH 2 ) 4 CH (NH 2 ) (COOH). 제4항에 있어서, 하기로 구성되는 군으로 부터 선택된 펩티드;The method of claim 4, further comprising: a peptide selected from the group consisting of: γ－Glu－Pro－Phe－N－MeHis－LVA－Ile－AMP 또는 L－ 히스티딘아미드, L－γ－글로타밀－L－프롤릴－L－페닐알라닐－N－〔2－히드록시－5－메틸－1－(2－메틸 프로필)－4－〔〔〔2－메틸－1－〔〔(2－피리디닐메틸)아미노〕카르보닐〕부틸〕아미노〕카르보닐〕헥실〕－Nα－메틸,〔1S－〔1R*, 2R*, 4R* (1R*,2R*)〕〕－, 트리스(트리플루오로아세테이트)(염);γ－Glu－Pro－Phe－N－MeHis－LVA－Ile－AMP－NO 또는 L－ 히스티딘아미드, L－γ－글루타밀－L－프롤릴－L－페닐알라닐－N－〔2－히드록시－5－메틸－1－(2－메틸프로필)－4－〔〔2－메틸－1－〔〔(2－피리디닐메틸)아미노〕카르보닐〕부틸〕아미노〕카르보닐〕헥실〕－Na－메틸, N－산화물〔1S－〔1R*, 2R*, 4R*(1R*,2R*)〕〕－, 트리스(트리플루오로아세테이트)(염); γ－Glu－Pro－Phe－N－MeHis－CVG 또는 L－히스티딘아미드, L－γ－글루타밀－L－프롤릴－L－페닐알라닐－N－〔1－시클로헥실메틸)－2,3－디히드록시－5－메틸헥실〕－Na－메틸－〔1S－(1R*, 2R*, 3R*)비스(트리플루오로아세테이트)(염); γ－Glu－Pro－(OCH3)Tyr－His－CVG 또는 L－히스티딘아미드, L－γ－글루타밀－L－프롤릴－0－메틸－L－티로실－N－〔1－시클로헥실메틸)－2,3－디히드록시－5－메틸헥실〕〔1R*, 2R*, 3R*〕－비스(트리플루오로아세테이트)(염); γ－Glu－Pro－Phe－N－MeHis－LVA－Ile－NH(CH2)4CH(COOH)(NH2) 또는 L－리신, N6－〔5－〔〔N－〔N－(1－D－γ－글루타밀－L－프롤릴)－L－페닐알라닐〕－N－메틸－L－히스티닐〕아미노〕－4－히드록시－7－메틸－2－(1－메틸에틸)－1－옥소옥틸〕－L－이소류실〕－〔2S－(2R*, 4R*, 5R*)〕－트리스(트리플루오로아세테이트)(염); γ－Glu－Pro－Phe－N－MeHis－CVA－Ile－NH(CH2)4CH(COOH)(NH2) 또는 L－리신, N6－〔N－〔6－시클로헥실－5－〔〔N－－(1－L－γ－글루타밀－L－프롤릴)－L－페닐알라닐)－N－메틸－L－히스티닐〕아미노〕－4－히드록시－2－(1－메틸에틸)－1－옥소헥실〕－L－이소류실〕－〔2S－(2R*, 4R*, 5R*)〕－, 트리스(트리플루오로아세테이트)(염);γ－Glu－Pro－Phe－N－MeHis－CVA－Ile－NH(CH2)4CH(COOH)(NH2) 또는 L－히스티딘아미드, L－γ－글루타밀－L－프롤릴－L－페닐알라닐－N－〔4－〔〔(5－아미노－5－카르목시펜틸)아미노〕카르보닐〕－1(시클로헥실 메틸)－2－히드록시－5－메틸헥실〕－N α－메틸－, 〔1S－(1R*, 2R*, 4R*(R*)〕〕－, 트리스(트리플루오로아세테이트)(염);γ－Glu－Pro－Phe－N－MeHis－CVA－MBA 또는 L－히스티딘아미드, L－γ－글루타밀－L－프롤릴－L－페닐알라닐－N－시클로헥실메틸－2－디히드록시－5－메틸－4－〔〔(2－메틸부틸)아미노〕카르보닐〕헥실〕Nα－메틸,〔1S－(1R*, 2R*, 4R*－(R*)〕〕－, 비스(트리플루오로아세테이트)(염);γ－Glu－Pro－Phe－N－MeHis－CVA－AMP 또는 L－히스티딘아미드, L－γ－글루타밀－L－프롤릴－L－페닐알라닐－N－〔1－(시클로헥실 메틸)－2－히드록시－5－메틸－4－〔〔〔(2－메틸－1－〔〔(2－피리디니리메틸)아미노〕카르보닐〕부틸〕－아미노〕헥실〕－N－메틸, 〔1S－(1R*, 2R*, 4R*(1R*,2R*)〕－, 트리스(트리플루오로아세테이트)(염);γ－Glu－Pro－Phe－N－MeHis－CVA－Ile－MBA－NO 또는 L－히스티딘아미드, L－γ－글루타밀－L－프롤릴－L－페닐알라닐－N－〔1－(시클로헥실메틸)－2－디히드록시－5－메틸－4－〔〔〔(2－메틸－1－〔〔(2－피리디니리메틸)아미노〕카르보닐〕부틸〕－아미노〕카르보닐〕헥실〕－N α－메틸, N－산화물, 〔1S－(1R*, 2R*, 4R*(1R*,2R*)〕－,트리스(트리플루오로아세테이트)(염);γ－Glu－Pro－Phe－N－MeHis－LVA－AMP－MBA 또는 L－히스티딘아미드, L－γ－글루타밀－L－프롤릴－L－페닐알라닐－N－〔2－히드록시－5－메틸－4－〔〔(2－메틸부틸)－아미노〕카르보닐〕－1－(2－메틸 프로필)헥실〕－N－메틸,〔1S－(1R*, 2R*, 4R*－(R*)〕〕－, 비스(트리플루오로아세테이트)(염);γ－Glu－Phe－－Asp－LVA－MBA 또는 L－아스파라진, N2－(N－L－γ－글루타밀－L－페닐알라닐)－N－〔2－히드록시－5－메틸－4－〔〔(2－메틸부틸)아미노〕카르보닐〕－1－(2－메킬프로필)헥실〕, 〔1S－(1R*, 2R*, 4R*－(R*)〕〕－, 비스(트리플루오로아세테이트)(염);γ－Glu－Phe－N－MeHis－LVA－Ile－AMP또는 L－히스티딘아미드,L－γ－글루타밀－L－페닐알라닐－N－〔2－히드록시－5－메틸－1－(2－메틸프로필)－4－〔〔〔(2－메틸〕－〔〔(2－피리디닐메틸)아미노〕카르보닐〕부틸〕아미노〕카르보닐〕헥실〕－Nα－메틸, 〔1S－(1R*, 2R*, 4R*(1R*,2R*)〕－,트리스(트리플루오로아세테이트)(염);－Glu－Phe－N－MeHis－LVA－MBA 또는 L－히스티딘아미드, L－γ－글루타밀－L－페닐알라닐－N－〔2－히드록시－5－메틸－4－〔〔〔(2－메틸부틸)아미노〕카르보닐〕－1－(2－메틸프로필)헥실〕－Nα－메틸,〔1S－(1R*, 2R*, 4R*(R*)〕〕－, 비스(트리플루오로아세테이트)(염);γ－Glu－Phe－N－MeHis－CVA－MBA또는 L－히스티딘아미드,L－γ－글루타밀－L－페닐알라닐－N－〔1(시클로헥실메틸)－2－히드록시－5－메틸－4－〔〔(2－메틸부틸)아미노〕카르보닐〕헥실〕－Nα－메틸, 〔1S－(1R*, 2R*, 4R*(R*)〕〕－, 비스(트리플루오로아세테이트)(염);γ－Glu－Phe－N－MeHis－LVA－AMP－NO 또는 L－히스티딘아미드, L－γ－글루타밀－L－프롤릴－L－페닐알라닐－N－〔2－히드록시－5－메틸－1－(2－메틸프로필)－4－〔〔(2－메틸－1－〔〔(2－피리디닐메틸)아미노〕카르보닐〕－2－메틸부틸)아미노〕－카르보닐〕헥실〕－N－메틸, N－산화물, 〔1S－(1R*, 2R*, 4R*(1R*,2R*)〕〕－,트리스(트리플루오로아세테이트)(염); 또는γ－Glu－Phe－N－MeHis－CVA－Ile－AMP－NO 또는 L－히스티딘아미드, L－γ－글루타밀－L－페닐알라닐－N－〔1－(시클로헥실메틸)－2－히드록시－5－메틸－4－〔〔(2－부틸－1－〔〔(2－피리디닐메틸)아미노〕카르보닐〕부틸)아미노－카르보닐〕헥실〕－N－메틸, N－산화물, 〕－〔1S－(1R*, 2R*, 4R*(1R*,2R*)〕〕－,트리스(트리플루오로아세테이트)(염);γ-Glu-Pro-Phe-N-MeHis-LVA-Ile-AMP or L-histidineamide, L-γ-glotamyl-L-prolyl-L-phenylalanyl-N- [2-hydroxy-5 -Methyl-1- (2-methylpropyl) -4-[[[2-methyl-1-[[(2-pyridinylmethyl) amino] carbonyl] butyl] amino] carbonyl] hexyl] -Nα-methyl , [1S- [1R *, 2R *, 4R * (1R *, 2R *)]]-tris (trifluoro acetate) (salt); γ-Glu-Pro-Phe-N-MeHis-LVA-Ile -AMP-NO or L-histidineamide, L- (gamma) -glutamyl-L-prolyl-L-phenylalanyl-N- [2-hydroxy-5-methyl- 1- (2-methylpropyl) -4 -[[2-methyl-1-[[(2-pyridinylmethyl) amino] carbonyl] butyl] amino] carbonyl] hexyl] -Na-methyl, N-oxide [1S- [1R *, 2R *, 4R * (1R *, 2R *)]], Tris (trifluoroacetate) (salt); γ-Glu-Pro-Phe-N-MeHis-CVG or L-histidineamide, L-γ-glutamyl-L-prolyl-L-phenylalanyl-N- (1-cyclohexylmethyl) -2,3 -Dihydroxy-5-methylhexyl] -Na-methyl- [1S- (1R *, 2R *, 3R *) bis (trifluoroacetate) (salt); γ-Glu-Pro- (OCH 3 ) Tyr-His-CVG or L-histidineamide, L-γ-glutamyl-L-prolyl-0-methyl-L-tyrosyl-N- [1-cyclohexylmethyl ) -2,3-dihydroxy-5-methylhexyl] [1R *, 2R *, 3R *] -bis (trifluoro acetate) (salt); γ-Glu-Pro-Phe-N-MeHis-LVA-Ile-NH (CH 2 ) 4 CH (COOH) (NH 2 ) or L-lysine, N6-[[N- [N- (1-) D- [gamma] -glutamyl-L-prolyl) -L-phenylalanyl] -N-methyl-L-histinyl] amino] -4-hydroxy-7-methyl- 2- (1-methylethyl)- 1-oxooctyl] -L-iso-chamber]-[2S- (2R *, 4R *, 5R *)]-tris (trifluoroacetate) (salt); γ-Glu-Pro-Phe-N-MeHis-CVA-Ile-NH (CH 2 ) 4 CH (COOH) (NH 2 ) or L-lysine, N6--N- [6-cyclohexyl-5-[[ N-(1-L-γ-glutamyl-L-prolyl) -L-phenylalanyl) -N-methyl-L-histinyl] amino] -4-hydroxy-2- (1-methylethyl ) -1-oxohexyl] -L-iso-chamber]-[2S- (2R *, 4R *, 5R *)]-, tris (trifluoro acetate) (salt); γ-Glu-Pro-Phe-N -MeHis-CVA-Ile-NH (CH 2 ) 4 CH (COOH) (NH 2 ) or L-histidineamide, L-γ-glutamyl-L-prolyl-L-phenylalanyl-N- [4- [((5-amino-5-carmocypentyl) amino] carbonyl] -1 (cyclohexyl methyl) -2-hydroxy-5-methylhexyl] -N alpha -methyl-, [1S- (1R * , 2R *, 4R * (R *)]]-, Tris (trifluoroacetate) (salt); γ-Glu-Pro-Phe-N-MeHis-CVA-MBA or L-histidineamide, L-γ- Glutamyl-L-Prolyl-L-Phenylala Nyl-N-cyclohexylmethyl-2-dihydroxy-5-methyl-4- [[((2-methylbutyl) amino] carbonyl] hexyl] Nα-methyl, [1S- (1R *, 2R *, 4R) *-(R *)]]-, bis (trifluoroacetate) (salt); γ-Glu-Pro-Phe-N-MeHis-CVA-AMP or L-histidineamide, L-γ-glutamyl-L -Prolyl-L-phenylalanyl-N- [1- (cyclohexyl methyl) -2-hydroxy-5-methyl-4-[[[(2-methyl-l-[[(2-pyridiniri Methyl) amino] carbonyl] butyl] -amino] hexyl] -N -Methyl, [1S- (1R *, 2R *, 4R * (1R *, 2R *)]-, tris (trifluoroacetate) (salt); γ-Glu-Pro-Phe-N-MeHis-CVA- Ile-MBA-NO or L-histidineamide, L-γ-glutamyl-L-prolyl-L-phenylalanyl-N- [1- (cyclohexylmethyl) -2-dihydroxy-5-methyl- 4-[[[((2-methyl-1-[[(2-pyridinylmethyl) amino] carbonyl] butyl] -amino] carbonyl] hexyl] -N α -methyl, N-oxide, [1S- (1R *, 2R *, 4R * (1R *, 2R *))-tris (trifluoroacetate) (salt); γ-Glu-Pro-Phe-N-MeHis-LVA-AMP-MBA or L- Histidineamide, L-γ-glutamyl-L-prolyl-L-phenylalanyl-N- [2-hydroxy-5-methyl-4-[((2-methylbutyl) -amino] carbonyl]- 1- (2-methylpropyl) hexyl] -N -Methyl, [1S- (1R *, 2R *, 4R *-(R *)]]-, bis (trifluoro acetate) (salt); γ-Glu-Phe- -Asp-LVA-MBA or L-asparagine, N2- (N-L-γ-glutamyl-L-phenylalanyl) -N- [2-hydroxy-5-methyl-4-[((2- Methylbutyl) amino] carbonyl] -1- (2-methylpropyl) hexyl], [1S- (1R *, 2R *, 4R *-(R *)]]], bis (trifluoroacetate) (salt γ-Glu-Phe-N-MeHis-LVA-Ile-AMP or L-histidineamide, L-γ-glutamyl-L-phenylalanyl-N- (2-hydroxy-5-methyl-1- (2-methylpropyl) -4-[[[(2-methyl]-[[(2-pyridinylmethyl) amino] carbonyl] butyl] amino] carbonyl] hexyl] -Nα-methyl, [1S- ( 1R *, 2R *, 4R * (1R *, 2R *)]-, tris (trifluoroacetate) (salt); -Glu-Phe-N-MeHis-LVA-MBA or L-histidineamide, L-γ-glutamyl-L-phenylalanyl-N- [2-hydroxy-5-methyl-4-[[(2 -Methylbutyl) amino] carbonyl] -1- (2-methylpropyl) hexyl] -Nα-methyl, [1S- (1R *, 2R *, 4R * (R *)]]-, bis (trifluoro Acetate) (salt); γ-Glu-Phe-N-MeHis-CVA-MBA or L-histidineamide, L-γ-glutamyl-L-phenylalanyl-N- [1 (cyclohexylmethyl) -2- Hydroxy-5-methyl-4-[[(2-methylbutyl) amino] carbonyl] hexyl] -Nα-methyl, [1S- (1R *, 2R *, 4R * (R *)]]], bis (Trifluoroacetate) (salt); γ-Glu-Phe-N-MeHis-LVA-AMP-NO or L-histidineamide, L-γ-glutamyl-L-prolyl-L-phenylalanyl-N -[2-hydroxy-5-methyl- 1- (2-methylpropyl) -4-[[(2-methyl-l-[[(2-pyridinylmethyl) amino] carbonyl] -2- Butyl-butyl) amino] - carbonyl] hexyl] -N -Methyl, N-oxide, [1S- (1R *, 2R *, 4R * (1R *, 2R *)]]-, tris (trifluoro acetate) (salt); or γ-Glu-Phe-N- MeHis-CVA-Ile-AMP-NO or L-histidineamide, L-γ-glutamyl-L-phenylalanyl-N- [1- (cyclohexylmethyl) -2-hydroxy-5-methyl-4- [[(2-butyl-1-[((2-pyridinylmethyl) amino] carbonyl] butyl) amino-carbonyl] hexyl] -N -Methyl, N-oxide,]-[1S- (1R *, 2R *, 4R * (1R *, 2R *)]]-, tris (trifluoro acetate) (salt); 제3항에 있어서, A6은 일반식 L1(이때, X1은 H2NC(CH3)2－이고, n은 1이다)의 일가부분이고; C7은 부재하고; C8은 Phe 또는 그의 유도체이고; D9는 N－MeHis, β－Asp 또는 그의 유도체이고; E10－F11은 LVA, CVA, 또는 그의 유도체이고; C12는 부재하거나, Ile 또는 그의 유도체이고; H13은 AMP, AMP－NO, MBA NH(CH2)4CH(NH2)(COOH), Ampip 또는 NH－CH((CH2)4(NH2)C(O)－Ampip 인 펩티드.The compound of claim 3, wherein A 6 is a monovalent moiety of the general formula L 1 wherein X 1 is H 2 NC (CH 3 ) 2 — and n is 1; C 7 is absent; C 8 is Phe or a derivative thereof; D 9 is N-MeHis, β-Asp or a derivative thereof; E 10 -F 11 is LVA, CVA, or a derivative thereof; C 12 is absent or Ile or a derivative thereof; H 13 is a peptide which is AMP, AMP-NO, MBA NH (CH 2 ) 4 CH (NH 2 ) (COOH), Ampip or NH-CH ((CH 2 ) 4 (NH 2 ) C (O) -Ampip. 제6항에 있어서, 하기로 구성되는 군으로 부터 선택된 펩티드:The peptide of claim 6 selected from the group consisting of: β－Val－Phe－N－MeHis－LVA－Ile－AMP－NO 또는 L－히스티딘아미드, N－(3－아미노－3－메틸－1－옥소부틸)－L－페닐알라닐－N－2－히드록시－5－메틸－1－(2－메틸프로필)－4－〔〔〔2－메틸－1－〔〔(2－피리디닐메틸)아니모〕카르보닐〕－부틸〕아미노〕카르보닐〕헥실〕－N α－메틸, N－산화물, 〔1S－(1R*, 2R*, 4R*(1R*,2R*)〕〕－비스(트리플루오로아세테이트)(염);β－Val－Phe－N－MeHis－CAV－Ile－AMP 또는 L－히스티딘아미드, N－(3－아미노－3－메틸－1－옥소부틸)－L－페닐알라닐－N－〔1－(시클로헥실메틸)－2－히드록시－5－메틸－4－〔〔2－메틸부틸)아미노〕카르보닐〕헥실〕－－N α－메틸,〔1S－(1R*, 2R*, 4R*(R*)〕〕－,비스(트리플루오로아세테이트)(염);β－Val－Phe－N－MeHis－CAV－Ile－AMP 또는 L－히스티딘아미드, N－(3－아미노－3－메틸－1－옥소부틸)－L－페닐알라닐－N－〔1－(시클로헥실메틸)－2－히드록시－5－메틸－4－〔〔〔2－메틸－1－〔〔(2－피리디닐메틸)아미노〕카르보닐〕－부틸〕아미노〕카르보닐〕헥실〕－N α－메틸, N－산화물, 〔1S－(1R*, 2R*, 4R*(1R*,2R*)〕〕－트리스(트리플루오로아세테이트)(염);－Val－Phe－N－MeHis－CVA－Ile－AMP－NO 또는 L－히스티딘아미드, N－(3－아미노－3－메틸－1－옥소부틸)－L－페닐알라닐－N－〔1－(시클로헥실메틸)－2－히드록시－5－메틸－4－〔〔〔2－메틸－1－〔〔(2－피리디닐메틸)아미노〕카르보닐〕－부틸〕아미노〕카르보닐〕헥실〕－N α－메틸, 〔1S－(1R*, 2R*, 4R*(1R*,2R*)〕〕－트리스(트리플루오로아세테이트)(염);β－Val－Phe－－Asp－LVA－MBA 또는 L－아스파라진, N2－〔N－(3－아미노－3－메틸－1－옥소부틸)－L－페닐알라닐－N－〔2－히드록시－5－메틸－4－〔〔(2－메틸부틸〕아미노〕카르보닐〕－1－(2－메틸프로필)헥실〕－〔1S－(1R*,2R*, 4R*(R*)〕〕－모노(트리플루오로아세테이트)(염);β－Val－Phe－β－Asp－LVA－Ile－AMP 또는 L－아스파라진, N2－〔N－(3－아미노－3－메틸－1－옥소부틸)－L－페닐알라닐－N－〔2－히드록시－5－메틸－1－(2－메틸프로필)4－〔〔〔2－메틸－1－〔〔(2－피리디닐메틸)아미노〕카르보닐〕부틸〕아미노〕카르보닐〕헥실〕－,〔1S－(1R*, 2R*, 4R*(1R*,2R*)〕〕－비스(트리플루오로아세테이트)(염);－Val－Phe－N－MeHis－LVA－MBA 또는 L－히스티딘아미드, N－(3－아미노－3－메틸－1－옥소부틸)－L－페닐알라닐－N－〔2－히드록시－5－메틸－4－〔〔(2－메틸부메틸)아미노〕카르보닐〕－1－(2－메틸프로필)헥실〕－N α－메틸,〔1S－(1R*,2R*, 4R*(R*)〕〕－비스(트리플루오로아세테이트)(염);β－Val－Phe－N－MeHis－LVA－Ile－AMP 또는 L－히스티딘아미드, N－(3－아미노－3－메틸－1－옥소부틸)－L－페닐알라닐－N－〔2－히드록시－5－메틸－1－(2－메틸프로필)－4－〔〔〔2－메틸－1－〔〔(2－피리디닐메틸)아미노〕카르보닐〕부틸〕아미노〕카르보닐〕헥실〕－N α－메틸,〔1S－(1R*, 2R*, 4R*(1R*,2R*)〕〕－트리스(트리플루오로아세테이트)(염);β－Val－Phe－NC(CH3)His－LVA－Ile－NC(CH2)4CH(COOH)(NH2) 또는 L－리신, N6－〔N－〔5－〔〔N－〔N－(3－아미노－3－메틸－1－옥소부틸)－L－페닐알라닐〕－N－메틸－L－히스티딜〕아미노〕－4－히드록시－7－메틸－2－(1－메틸에틸)－1－옥소부틸〕－L－이소류실〕－,〔2S－〔2R*, 4R*, 5R*)〕－트리스(트리플루오로아세테이트)(염);β－Val－Phe－NC(CH3)His－CVA－Ile－NC(CH2)4CH(COOH)(NH2) 또는 L－리신, N6－〔N－〔5－〔〔N－〔N－(3－아미노－3－메틸－1－옥소부틸)－L－페닐알라닐〕－N－메틸－L－히스티딜〕아미노〕－6－4－히드록시－2－(1－메틸에틸)－1－옥소부틸〕－L－이소류실〕－,〔2S－〔2R*, 4R*, 5R*)〕－트리스(트리플루오로아세테이트)(염);β－Val－Phe－NC(CH3)His－CVA－Ile－NC(CH2)4CH(COOH)(NH2) 또는 L－히스티딘아미드, N－(3－아미노－3－메틸－1－옥소부틸)－L－페닐알라닐〕－N－메틸－〔4－〔〔(5－아미노－5－카르복시펜틸)아미노〕카르보닐〕－1－(시클로헥실메틸)－2－히드록시－5－메틸헥신〕－Nα－,〔1S－(1R*,2R*,(1R*)〕〕－트리스(트리플루오로아세테이트)(염);－Val－Phe－NC(CH3)His－LVA－Ile－AmPip 또는 L－히스티딘아미드,N－(3－아미노－3－메틸－1－옥소부틸)－L－페닐알라닐－N－〔2－히드록시－5－메틸－1－(2－메틸프로필)－〔4－〔〔〔2－메틸－1－〔〔(4－피페리딜메틸)아미노〕카르보닐〕부틸〕아미노〕카르보닐〕헥실〕－N α－메틸, 〔1S－〔1R*, 2R*, 4R*(1R*,2R*)〕〕－, 트리스(트리플루오로아세테이트)(염); β－Val－Phe－NC(CH3)His－LVA－NH－CH((CH2)4)C(O)－AmPip 또는 L－히스티딘아미드,N－(3－아미노－3－메틸－1－옥소부틸)－L－페닐알라닐－N－〔2－히드록시－5－메틸－1－(4－아미노부틸)－4－〔〔〔2－메틸－1－〔〔(4－피페리딜메틸)아미노〕카르보닐〕부틸〕아미노〕카르보닐〕헥실〕－N α－메틸, 〔1S－〔1R*, 2R*, 4R*(1R*,2R*)〕〕－, 테트라비스(트리플루오로아세테이트)(염);β-Val-Phe-N-MeHis-LVA-Ile-AMP-NO or L-histidineamide, N- (3-amino-3-methyl-1-oxobutyl) -L-phenylalanyl-N-2- Hydroxy-5-methyl-l- (2-methylpropyl) -4-[[[2-methyl-l-[((2-pyridinylmethyl) animo] carbonyl] -butyl] amino] carbonyl] Hexyl] -N α -methyl, N-oxide, [1S- (1R *, 2R *, 4R * (1R *, 2R *)]]-bis (trifluoroacetate) (salt); β-Val-Phe -N-MeHis-CAV-Ile-AMP or L-histidineamide, N- (3-amino-3-methyl- 1-oxobutyl) -L-phenylalanyl-N- (1- (cyclohexylmethyl)- 2-hydroxy-5-methyl-4-[[2-methylbutyl) amino] carbonyl] hexyl] -N α-methyl, [1S- (1R *, 2R *, 4R * (R *)]] -, Bis (trifluoroacetate) (salt); β-Val-Phe-N-MeHis-CAV-Ile-AMP or L-histidineamide, N- (3-amino-3-methyl-1-oxobutyl) L-phenylalanyl-N- [1- (cyclohexylmethyl) -2-hydroxy-5-methyl-4-[[[2-methyl-1-[[(2-pyridinylmethyl) amino] carbonyl ] -Butyl] amino] carbonyl] hexyl] -N alpha -methyl, N-oxide, [1S- (1R *, 2R *, 4R * (1R *, 2R *)]]]-tris (trifluoroacetate) (salt); -Val-Phe-N-MeHis-CVA-Ile-AMP-NO or L-histidineamide, N- (3-amino-3-methyl-1-oxobutyl) -L-phenylalanyl-N- [1- (Cyclohexylmethyl) -2-hydroxy-5-methyl-4-([[[2-methyl-1-[[(2-pyridinylmethyl) amino] carbonyl] -butyl] amino] carbonyl] hexyl] -N α -methyl, [1S- (1R *, 2R *, 4R * (1R *, 2R *)]]-tris (trifluoroacetate) (salt); β-Val-Phe- -Asp-LVA-MBA or L-asparagine, N2- (N- (3-amino-3-methyl- 1-oxobutyl) -L-phenylalanyl-N- [2-hydroxy-5-methyl- 4-[[(2-methylbutyl] amino] carbonyl] -1- (2-methylpropyl) hexyl]-[1S- (1R *, 2R *, 4R * (R *)]]-mono (trifluoro Low acetate) (salt); β-Val-Phe-β-Asp-LVA-Ile-AMP or L-asparagine, N2- (N- (3-amino-3-methyl-1-oxobutyl) -L- Phenylalanyl-N- [2-hydroxy-5-methyl-l- (2-methylpropyl) 4-[[[2-methyl-l-[[(2-pyridinylmethyl) amino] carbonyl] butyl [Amino] carbonyl] hexyl]-, [1S- (1R *, 2R *, 4R * (1R *, 2R *)]]-bis (trifluoroacetate) (salt); -Val-Phe-N-MeHis-LVA-MBA or L-histidineamide, N- (3-amino-3-methyl- 1-oxobutyl) -L-phenylalanyl-N- [2-hydroxy-5 -Methyl-4-[[(2-methylbutmethyl) amino] carbonyl] -1- (2-methylpropyl) hexyl] -N α-methyl, [1S- (1R *, 2R *, 4R * (R *)]] -Bis (trifluoroacetate) (salt); β-Val-Phe-N-MeHis-LVA-Ile-AMP or L-histidineamide, N- (3-amino-3-methyl-1- Oxobutyl) -L-phenylalanyl-N- [2-hydroxy-5-methyl- 1- (2-methylpropyl) -4-[[[2-methyl-l-[[(2-pyridinylmethyl ) Amino] carbonyl] butyl] amino] carbonyl] hexyl] -N α -methyl, [1S- (1R *, 2R *, 4R * (1R *, 2R *)]]]-tris (trifluoroacetate) (Salt); β-Val-Phe-NC (CH 3 ) His-LVA-Ile-NC (CH 2 ) 4 CH (COOH) (NH 2 ) or L-lysine, N6-[N- [5-[[ N- [N- (3-amino-3-methyl-1 Oxobutyl) -L-phenylalanyl] -N-methyl-L-histidyl] amino] -4-hydroxy-7-methyl-2- (1-methylethyl) -1-oxobutyl] -L-iso ryusil] -, [2S- [2R *, 4R *, 5R * ) ] - tris (trifluoroacetate) (salt); β-Val-Phe- NC (CH 3) His-CVA-Ile-NC (CH 2) 4 CH (COOH) ( NH 2) or L- lysine, N6- [N- [5 - [[N- [N- (3- amino-3-methyl-1-oxobutyl) phenyl -L- Allah Nil] -N-methyl-L-histidyl] amino] -6-4-hydroxy-2- (1-methylethyl) -1-oxobutyl] -L-isoisosil]], [2S- [2R * , 4R *, 5R *)]-tris (trifluoroacetate) (salt); β-Val-Phe-NC (CH 3 ) His-CVA-Ile-NC (CH 2 ) 4 CH (COOH) (NH 2 ) Or L-histidineamide, N- (3-amino-3-methyl-1-oxobutyl) -L-phenylalanyl] -N-methyl- [4-([(5-amino-5-carboxypentyl) Amino] carbonyl] -1-(cyclohexyl me ) -2-hydroxy-5-methyl-hexyne] -Nα -, [1S- (1R *, 2R *, (1R *)]] - tris (trifluoroacetate) (salt); -Val-Phe-NC (CH 3 ) His-LVA-Ile-AmPip or L- histidine amide, N- (3- amino-3-methyl-1-oxobutyl) phenyl -L- alanyl -N- [2 -Hydroxy-5-methyl-l- (2-methylpropyl)-[4-[[[2-methyl-l-[(4-piperidylmethyl) amino] carbonyl] butyl] amino] carbonyl ] Hexyl] -N alpha -methyl, [1S- [1R *, 2R *, 4R * (1R *, 2R *)]]-, tris (trifluoroacetate) (salt); β-Val-Phe-NC (CH 3 ) His-LVA-NH-CH ((CH 2 ) 4 ) C (O) -AmPip or L-histidineamide, N- (3-amino-3-methyl-1- Oxobutyl) -L-phenylalanyl-N- [2-hydroxy-5-methyl-l- (4-aminobutyl) -4-[[[2-methyl-l-[[(4-piperidyl Methyl) amino] carbonyl] butyl] amino] carbonyl] hexyl] -N α-methyl, [1S- [1R *, 2R *, 4R * (1R *, 2R *)]]], tetrabis (trifluoro) Low acetate) (salts); 제3항에 있어서, A6은 일반식 L1(이때, X1은 (HO)2P(O,O－이고, n은 1 또는 3이다)의 일가부분이고; C7은 부재하거나; Pro 또는 그의 유도체이고; C8은 Phe, 또는 그의 유도체이고; D9는 β－Asp, N－MeHis 또는 그의 유도체이고; E10－F11은 LVA, CVG 또는 그의 유도체이고; G12는 부재하거나, Ile 또는 그의 유도체이고; H13은 부재하거나 AMP, AMP－NO 또는 MBA인 펩티드.The compound of claim 3, wherein A 6 is a monovalent moiety of the general formula L 1 , wherein X 1 is (HO) 2 P (O, O—, n is 1 or 3); C 7 is absent; Or a derivative thereof; C 8 is Phe, or a derivative thereof; D 9 is β-Asp, N-MeHis or a derivative thereof; E 10 -F 11 is LVA, CVG or a derivative thereof; G 12 is absent, Ile or a derivative thereof, wherein H 13 is absent or is AMP, AMP-NO or MBA. 제8항에 있어서, 하기로 구성되는 군으로 부터 선택된 펩티드;The method of claim 8, further comprising: a peptide selected from the group consisting of: (HO)2P(O)OCH2C(O)－Phe－β－Asp－LVA－Ile－AMP 또는 L－아스파라진, N－〔2－히드록시－5－메틸－1－(2－메틸프로필)－4－〔〔〔2－메틸－1〔〔2－피리디닐메틸)아미노〕카르보닐〕부틸〕아미노〕카르보닐〕헥실－N2－〔N－〔(포스포녹시)아세틸〕－L－페닐알라닐〕－, 모노히드로클로라이드, 〔1S－(1R*, 2R*, 4R*－(1R*,2R*)〕〕－;(HO)2P(O)OCH2C(O)－Phe－N－MeHis－LVA－Ile－AMP 또는 L－히스티딘아미드, N－〔(포스포노옥시)아세틸〕－L－페닐아라닐－N－〔2－히드록시－5－메틸－1－(2－메틸프로필)－4－〔〔〔2－메틸－1〔〔2－피리디닐메틸)아미노〕카르보닐〕부틸〕아미노〕카르보닐〕헥실－N α－메틸－, 디히드로클로로라이드〔1S－(1R*,2R*,4R*－(1R*,2R*)〕〕－;(HO)2P(O)OCH2C(O)－Pro－Phe－N－MeHis－LVA－Ile－AMP 또는 L－히스티딘아미드, N－〔N－1－〔(포스포노옥시)아세틸〕－N－프롤릴〕－L－페닐알라닐－N－〔2－히드록시－5－메틸－1－(2－메틸프로필)－4－〔〔〔2－메틸－1〔〔2－피리디닐메틸)아미노〕카르보닐〕부틸〕아미노〕카르보닐〕헥실－Nα－메틸－,디히드로클로로라이드〔1S－(1R*,2R*,4R*－(1R*,2R*)〕〕－;(HO)2P(O)OCH2C(O)－Pro－Phe－N－MeHis－LVA－Ile－AMP－NO 또는 L－히스티딘아미노, 1－〔(포스포노옥시)아세틸〕－N－프롤릴〕－L－페닐알라닐－N－〔2－히드록시－5－메틸－1－(2－메틸프로필)－4－〔〔〔2－메틸－1〔〔2－피리디닐메틸)아미노〕카르보닐〕부틸〕아미노〕카르보닐〕헥실－Nα－메틸, N－산화물, 디히드로클로라이드 〔1S－(1R*,2R*,4R*－(1R*,2R*)〕〕－;(HO)2P(O)OCH2C(O)－Pro－Phe－N－MeHis－LVA－Ile－AMP－NO 또는 L－히스티딘아미노, N－〔(1－〔1－옥소－4－(포스포노옥시)부틸〕－3－피롤리디닐〕카르보닐〕－L－페닐알라닐－N－〔2－히드록시－5－메틸－1－(2－메틸프로필)－4－〔〔〔2－메틸－1〔〔2－2－피리디닐메틸)아미노〕카르보닐〕부틸〕아미노〕카르보닐〕헥실－Nα－메틸,디히드로클로라이드〔1S－(1R*,(SR*),2R*,4R*(1R*)〕〕－(HO)2P(O)OCH2C(O)－Pro－Phe－N－MeHis－LVA－Ile－AMP 또는 L－히스티딘아미드 N－〔(1－〔1－옥소－4－(포스포노옥시)부틸〕－3－피롤리디닐〕카르보닐〕－L－페닐알라닐－N－〔2－히드록시－5－메틸－1－(2－메틸프로필)－4－〔〔〔2－메틸－1〔〔2－2－피리디닐메틸)아미노〕－카르보닐〕부틸〕아미노〕카르보닐〕헥실－N－메틸,N－산화물,모노히드로클로라이드,〔1S－(1R*,－(SR*),2R*,4R*(1R*2R*)〕〕－;또는(HO)2P(O)OCH2C(O)－Pro－Phe－N－MeHis－CVG 또는 L－히스티딘아미노, 1－〔(포스포노옥시)아세틸〕－L－프롤릴－L－페닐알라닐－N－〔1－(시클로헥실메틸)－2,3－디히드록시－5－메틸헥실〕－N－메틸－,모노히드로클로로라이드,〔1S－〔1R*,2S*,3R*)〕－(HO) 2 P (O) OCH 2 C (O) -Phe-β-Asp-LVA-Ile-AMP or L-asparagine, N- [2-hydroxy-5-methyl- 1- (2-methyl Propyl) -4-[[[2-methyl-1 [[2-pyridinylmethyl) amino] carbonyl] butyl] amino] carbonyl] hexyl-N2- [N-[(phosphonoxy) acetyl] -L -Phenylalanyl]-, monohydrochloride, [1S- (1R *, 2R *, 4R *-(1R *, 2R *)]]-; (HO) 2 P (O) OCH 2 C (O)- Phe-N-MeHis-LVA-Ile-AMP or L-histidineamide, N-[(phosphonooxy) acetyl] -L-phenylalanyl-N- [2-hydroxy-5-methyl-l- (2 -Methylpropyl) -4-[[[2-methyl-1 [[2-pyridinylmethyl) amino] carbonyl] butyl] amino] carbonyl] hexyl-N alpha -methyl-, dihydrochlorolide [1S- (1R *, 2R *, 4R *-(1R *, 2R *)]]]; (HO) 2 P (O) OCH 2 C (O) -Pro-Phe-N-MeHis-LVA-Ile-AMP or L-histidine amide, N- [N-1-[(phosphono Oxy) acetyl] -N-prolyl] -L-phenylalanyl-N- [2-hydroxy-5-methyl- 1- (2-methylpropyl) -4-[[[2-methyl-1 [[ 2-pyridinylmethyl) amino] carbonyl] butyl] amino] carbonyl] hexyl-Nα-methyl-, dihydrochlorolide [1S- (1R *, 2R *, 4R *-(1R *, 2R *)] (HO) 2 P (O) OCH 2 C (O) -Pro-Phe-N-MeHis-LVA-Ile-AMP-NO or L-histidineamino, 1-((phosphonooxy) acetyl]- N-prolyl] -L-phenylalanyl-N- [2-hydroxy-5-methyl- 1- (2-methylpropyl) -4-[[[2-methyl-1 [[2-pyridinylmethyl ) Amino] carbonyl] butyl] amino] carbonyl] hexyl-Nα-methyl, N-oxide, dihydrochloride [1S- (1R *, 2R *, 4R *-(1R *, 2R *)]]; (HO) 2 P (O) OCH 2 C (O) -Pro-Phe-N-MeHis-LVA-Ile-AMP-NO or L-histidineamino, N-[(1- (1-oxo-4-( Phosphonooxy) butyl] -3-blood Lolidinyl] carbonyl] -L-phenylalanyl-N- [2-hydroxy-5-methyl-l- (2-methylpropyl) -4-[[[2-methyl-1 [[2--2-] Pyridinylmethyl) amino] carbonyl] butyl] amino] carbonyl] hexyl-Nα-methyl, dihydrochloride [1S- (1R *, (SR *), 2R *, 4R * (1R *)]]]-( HO) 2 P (O) OCH 2 C (O) -Pro-Phe-N-MeHis-LVA-Ile-AMP or L-histidineamide N-[(1- (1-oxo-4- (phosphonooxy)) Butyl] -3-pyrrolidinyl] carbonyl] -L-phenylalanyl-N- [2-hydroxy-5-methyl- 1- (2-methylpropyl) -4-[[[2-methyl-1 [[2--2-pyridinylmethyl) amino] -carbonyl] butyl] amino] carbonyl] hexyl-N -Methyl, N-oxide, monohydrochloride, [1S- (1R *,-(SR *), 2R *, 4R * (1R * 2R *)]]]; or (HO) 2 P (O) OCH 2 C (O) -Pro-Phe-N-MeHis-CVG or L-histidineamino, 1-[(phosphonooxy) acetyl] -L-prolyl-L-phenylalanyl-N- [1- (cyclohexyl Methyl) -2,3-dihydroxy-5-methylhexyl] -N -Methyl-, monohydrochlorolide, [1S- [1R *, 2S *, 3R *)] ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.※ Note: This is to be disclosed by the original application.
KR1019900702636A 1989-04-18 1990-04-05 Novel Linin Inhibitor Peptides with Polar N-Terminal Groups KR920700221A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33975089A 1989-04-18 1989-04-18
US07/339750 1989-04-18
PCT/US1990/001764 WO1990012804A2 (en) 1989-04-18 1990-04-05 Peptides having novel polar n-terminal groups

Publications (1)

Publication Number Publication Date
KR920700221A true KR920700221A (en) 1992-02-19

Family

ID=23330419

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900702636A KR920700221A (en) 1989-04-18 1990-04-05 Novel Linin Inhibitor Peptides with Polar N-Terminal Groups

Country Status (5)

Country Link
EP (1) EP0468998A1 (en)
JP (1) JPH04504716A (en)
KR (1) KR920700221A (en)
AU (1) AU5407190A (en)
WO (1) WO1990012804A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
DE4126485A1 (en) * 1991-08-10 1993-02-11 Bayer Ag TRIFLUOROMETHYL-CONTAINING PSEUDOPEPTIDE
WO1993006127A1 (en) * 1991-09-17 1993-04-01 Warner-Lambert Company Novel amino acid prodrug renin inhibitors
DE69333270T2 (en) 1992-03-11 2004-08-05 Narhex Ltd. AMINE DERIVATIVES OF OXO AND HYDROXY SUBSTITUTED CARBON HYDROGEN
US6071895A (en) * 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
US5888992A (en) * 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
WO1993018006A1 (en) * 1992-03-11 1993-09-16 Narhex Limited Amine derivatives of oxo- and hydroxy-substitued hydrocarbons
CZ229594A3 (en) * 1992-03-25 1995-04-12 Pfizer Peptides, process of their preparation, their use and pharmaceutical compositions based thereon
DE4215874A1 (en) * 1992-05-14 1993-11-18 Bayer Ag Dithiolanylglycine-containing HIV protease inhibitors of the hydroxyethylene isostear type

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3377497D1 (en) * 1982-09-15 1988-09-01 Haessle Ab Enzyme inhibitors
DE3830825A1 (en) * 1987-09-15 1989-03-23 Sandoz Ag Hydrophilic renin inhibitors, their preparation and use
EP0312157A3 (en) * 1987-10-13 1990-07-25 Merck & Co. Inc. Tetrapeptide renin inhibitors having a novel c-terminal amino acid

Also Published As

Publication number Publication date
WO1990012804A2 (en) 1990-11-01
JPH04504716A (en) 1992-08-20
EP0468998A1 (en) 1992-02-05
WO1990012804A3 (en) 1990-11-29
AU5407190A (en) 1990-11-16

Similar Documents

Publication Publication Date Title
KR920700221A (en) Novel Linin Inhibitor Peptides with Polar N-Terminal Groups
EP0231919B1 (en) N-heterocyclic alcohol renin inhibitors
ES2341949T3 (en) INHIBITORS WITH BICYCLE LACTAMA OF THE CONVERSORA ENZIMA INTERLEUCINA-1-BETA.
US6030946A (en) Reversible cysteine protease inhibitors
US4719288A (en) Substituted 5-amino-4-hydroxyvaleryl derivatives
CA2146059A1 (en) Imidazole-containing inhibitors of farnesyl protein transferase
AU2006204022B2 (en) Tripeptide and tetrapeptide thioethers
Roderick et al. Thiorphan and retro-thiorphan display equivalent interactions when bound to crystalline thermolysin
AU715765B2 (en) Serine protease inhibitors
JPH03500772A (en) Renin inhibitors containing (1-amino-2-hydroxy-2-heterocyclic) ethyl group
KR910004661A (en) LHRH homolog
EP0363284A2 (en) Use of peptidase inhibitors for the preparation of medicaments useful for the treatment of strokes
EP0258289A1 (en) Peptide analogs
KR910006324A (en) Peptidase and isomerase inhibitors
KR910006224A (en) Amino acid derivatives
KR890005148A (en) N-acylamino acid derivatives and uses thereof
NO20000231L (en) Dolastatin-15 derivatives
KR890006572A (en) Amino acid derivatives
US5643878A (en) 5-amino-4-hydroxyhexanoic acid derivatives
US6265382B1 (en) Dipeptide inhibitors of protein farnesyltransferase
US7910556B2 (en) PAR-2 agonist
KR900016114A (en) Amino acid derivatives
CA1338163C (en) Process for the preparation of n-alkylated dipeptides and their esters
KR950701935A (en) Conformationally restrained peptide analogs as antiplatelet agents
Dean Structure, function and subcellular localization of a human platelet Ca2+-ATPase

Legal Events

Date Code Title Description
WITB Written withdrawal of application